Cornerstone Wealth Group LLC Invests $5.69 Million in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cornerstone Wealth Group LLC acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,798 shares of the medical equipment provider’s stock, valued at approximately $5,693,000.

Other hedge funds have also recently bought and sold shares of the company. CWM LLC grew its holdings in shares of Intuitive Surgical by 26.4% during the 4th quarter. CWM LLC now owns 31,924 shares of the medical equipment provider’s stock valued at $10,770,000 after acquiring an additional 6,659 shares in the last quarter. MCF Advisors LLC increased its position in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Sage Mountain Advisors LLC increased its position in Intuitive Surgical by 6.1% in the 4th quarter. Sage Mountain Advisors LLC now owns 1,330 shares of the medical equipment provider’s stock worth $449,000 after purchasing an additional 77 shares during the last quarter. RWA Wealth Partners LLC raised its stake in shares of Intuitive Surgical by 1,354.5% during the 4th quarter. RWA Wealth Partners LLC now owns 22,327 shares of the medical equipment provider’s stock worth $7,532,000 after purchasing an additional 20,792 shares in the last quarter. Finally, PDS Planning Inc lifted its holdings in shares of Intuitive Surgical by 4.5% during the 4th quarter. PDS Planning Inc now owns 1,343 shares of the medical equipment provider’s stock valued at $453,000 after buying an additional 58 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 240 shares of Intuitive Surgical stock in a transaction on Monday, August 12th. The stock was sold at an average price of $464.76, for a total transaction of $111,542.40. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,558,968.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Craig H. Barratt sold 2,496 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total transaction of $1,005,613.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Robert Desantis sold 240 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total value of $111,542.40. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,558,968.56. The disclosure for this sale can be found here. Insiders sold 15,309 shares of company stock worth $6,642,470 in the last 90 days. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded down $3.88 during midday trading on Friday, reaching $486.55. 1,141,680 shares of the company’s stock were exchanged, compared to its average volume of 1,536,832. The company’s 50 day simple moving average is $448.30 and its two-hundred day simple moving average is $410.37. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $493.97. The firm has a market capitalization of $172.58 billion, a PE ratio of 87.40, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company earned $1.18 earnings per share. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ISRG shares. JPMorgan Chase & Co. raised their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Morgan Stanley increased their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. BTIG Research boosted their price target on Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Barclays increased their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $444.70.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.